中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
14期
851-854
,共4页
李金伟%李小波%肖海%王蓉%温盛瑛
李金偉%李小波%肖海%王蓉%溫盛瑛
리금위%리소파%초해%왕용%온성영
鼻咽肿瘤%放射治疗%分次剂量%远期疗效
鼻嚥腫瘤%放射治療%分次劑量%遠期療效
비인종류%방사치료%분차제량%원기료효
nasopharyngeal neoplasms%radiotherapy%dose fractionation%late efficacy
目的：探讨鼻咽癌后程加速超分割的远期疗效及并发症。方法：对2005年12月至2008年5月江西省赣州市肿瘤医院收治确诊为鼻咽癌的58例初治患者，随机分为后程加速超分割放疗组（研究组）和常规分割放疗组（对照组），两组开始均照射1次/天，2 Gy/次，5天/周，40～50 Gy后，研究组鼻咽部放疗2次/天，1.5 Gy/次，间隔>6 h，5天/周，总剂量73～76 Gy；对照组鼻咽部仍按常规分割放疗方法，放疗至70～76 Gy。总剂量相近，总疗程缩短0.5～1.5周。结果：研究组、对照组5年鼻咽肿瘤局控率分别为86%（25/29）、59%（17/29），差异有统计学意义（P=0.021）。研究组晚期放射损伤发生率比对照组稍增加，但差异无统计学意义。结论：后程加速超分割放疗能提高鼻咽癌的局控率，远期并发症未明显加重。
目的：探討鼻嚥癌後程加速超分割的遠期療效及併髮癥。方法：對2005年12月至2008年5月江西省贛州市腫瘤醫院收治確診為鼻嚥癌的58例初治患者，隨機分為後程加速超分割放療組（研究組）和常規分割放療組（對照組），兩組開始均照射1次/天，2 Gy/次，5天/週，40～50 Gy後，研究組鼻嚥部放療2次/天，1.5 Gy/次，間隔>6 h，5天/週，總劑量73～76 Gy；對照組鼻嚥部仍按常規分割放療方法，放療至70～76 Gy。總劑量相近，總療程縮短0.5～1.5週。結果：研究組、對照組5年鼻嚥腫瘤跼控率分彆為86%（25/29）、59%（17/29），差異有統計學意義（P=0.021）。研究組晚期放射損傷髮生率比對照組稍增加，但差異無統計學意義。結論：後程加速超分割放療能提高鼻嚥癌的跼控率，遠期併髮癥未明顯加重。
목적：탐토비인암후정가속초분할적원기료효급병발증。방법：대2005년12월지2008년5월강서성공주시종류의원수치학진위비인암적58례초치환자，수궤분위후정가속초분할방료조（연구조）화상규분할방료조（대조조），량조개시균조사1차/천，2 Gy/차，5천/주，40～50 Gy후，연구조비인부방료2차/천，1.5 Gy/차，간격>6 h，5천/주，총제량73～76 Gy；대조조비인부잉안상규분할방료방법，방료지70～76 Gy。총제량상근，총료정축단0.5～1.5주。결과：연구조、대조조5년비인종류국공솔분별위86%（25/29）、59%（17/29），차이유통계학의의（P=0.021）。연구조만기방사손상발생솔비대조조초증가，단차이무통계학의의。결론：후정가속초분할방료능제고비인암적국공솔，원기병발증미명현가중。
Objective:This work aims to explore the long-term efficacy and complications of late-course accelerated hyperfrac-tionation (LCAHF) for treating nasopharyngeal carcinoma. Methods:A total of 58 patients who consulted from December 2005 to May 2008 and histologically proven nasopharyngeal carcinoma at initial diagnosis were randomized into an LCAHF group (experimental group) and a conventional fractionation (CF) group (control group). The treatment dose for both groups was 2 Gy per fraction once dai-ly, 5 days a week. After the 40 Gy to 50 Gy dose, the dosage in the LCAHF group was increased to two daily doses at 1.5 Gy per frac-tion 6 h apart, 5 days a week. The total dose in this group was 73 Gy to 76 Gy, the total dose in the CF group was 70 Gy to 76 Gy, with the total course of the treatment shortened by 0.5 weeks to 1.5 weeks in the former group. Results:The 5-year control rates of the naso-pharyngeal cancers was 86% in the LCAHF group and 59% in the CF group (P=0.021), with statistically significant differences be-tween the two groups. The late complications slightly increased in the LCAHF group than in the CF group, but the differences were not statistically significant. Conclusion:LCAHF treatment improves the local control of nasopharyngeal carcinoma without increasing the incidence of long-term complications.
